When might Orforglipron become available?
The availability of Orforglipron, an oral non-peptide GLP-1 receptor agonist, is contingent on the completion of ongoing clinical trials and subsequent regulatory approvals. Eli Lilly and Company is developing Orforglipron, with clinical development actively underway [1]. The drug is being investigated for the treatment of obesity and type 2 diabetes [1][2].
What phase are Orforglipron's clinical trials in?
Orforglipron is currently in Phase 3 clinical development for obesity [1]. Phase 3 trials are the final stage of clinical testing before a drug can be submitted for regulatory approval, involving a larger number of participants to confirm efficacy and monitor side effects [3].
What is the mechanism of action for Orforglipron?
Orforglipron works by selectively targeting and activating the glucagon-like peptide-1 (GLP-1) receptor [1]. GLP-1 is a naturally occurring hormone that plays a role in regulating appetite and glucose metabolism [4]. By mimicking the action of GLP-1, Orforglipron is intended to reduce food intake and improve glycemic control [4][2]. Unlike injectable GLP-1 receptor agonists, Orforglipron is formulated for oral administration [1].
How does Orforglipron compare to other GLP-1 receptor agonists?
Orforglipron's key differentiator is its oral formulation, offering an alternative to the injectable GLP-1 receptor agonists that are currently available, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) [1][5]. The oral route of administration may offer increased convenience for patients [1]. Eli Lilly is developing both oral and injectable formulations of GLP-1 receptor agonists [1].
What are the potential risks and side effects of Orforglipron?
As with other GLP-1 receptor agonists, common side effects of Orforglipron are expected to include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation [2]. The safety and tolerability profile is being evaluated across the ongoing clinical trials [1].
What is the patent status of Orforglipron?
Information regarding specific patent exclusivity for Orforglipron is typically detailed by sources like DrugPatentWatch.com [6]. Patents are crucial for protecting the market exclusivity of new drugs, influencing when generic versions can enter the market.
Who is developing Orforglipron?
Orforglipron is being developed by Eli Lilly and Company [1].
Sources:
1. https://drugpatentwatch.com/blog/2023/11/orforglipron-oral-glp-1-receptor-agonist-progress-and-potential-impact/
2. https://www.drugpatentwatch.com/blog/2023/11/orforglipron-oral-glp-1-receptor-agonist-progress-and-potential-impact/
3. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
4. https://www.drugpatentwatch.com/blog/2023/11/orforglipron-oral-glp-1-receptor-agonist-progress-and-potential-impact/
5. https://drugpatentwatch.com/blog/2023/11/orforglipron-oral-glp-1-receptor-agonist-progress-and-potential-impact/
6. https://www.drugpatentwatch.com/